Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum

Sensitive detection of low-abundance proteins in complex biological samples has typically been achieved by immunoassays that use antibodies specific to target proteins; however, de novo development of antibodies is associated with high costs, long development lead times, and high failure rates. To address these challenges, we developed an antibody-free strategy that involves PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing) for sensitive selected reaction monitoring (SRM)–based targeted protein quantification. The strategy capitalizes on high-resolution reversed-phase liquid chromatographic separations for analyte enrichment, intelligent selection of target fractions via on-line SRM monitoring of internal standards, and fraction multiplexing before nano–liquid chromatography-SRM quantification. Application of this strategy to human plasma/serum demonstrated accurate and reproducible quantification of proteins at concentrations in the 50–100 pg/mL range, which represents a major advance in the sensitivity of targeted protein quantification without the need for specific-affinity reagents. Application to a set of clinical serum samples illustrated an excellent correlation between the results obtained from the PRISM-SRM assay and those from clinical immunoassay for the prostate-specific antigen level.

[1]  Scott R. Kronewitter,et al.  Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. , 2012, Journal of proteomics.

[2]  Richard D. Smith,et al.  Advancing the sensitivity of selected reaction monitoring‐based targeted quantitative proteomics , 2012, Proteomics.

[3]  T. Pawson,et al.  Selected reaction monitoring mass spectrometry reveals the dynamics of signaling through the GRB2 adaptor , 2011, Nature Biotechnology.

[4]  S. Carr,et al.  A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease , 2011, Nature Biotechnology.

[5]  Pei Wang,et al.  A targeted proteomics–based pipeline for verification of biomarkers in plasma , 2011, Nature Biotechnology.

[6]  Ronald J. Moore,et al.  Reversed‐phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells , 2011, Proteomics.

[7]  K. Kinzler,et al.  Mutant proteins as cancer-specific biomarkers , 2011, Proceedings of the National Academy of Sciences.

[8]  Susan E Abbatiello,et al.  Evaluation of Large Scale Quantitative Proteomic Assay Development Using Peptide Affinity-based Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.

[9]  R. Aebersold,et al.  A quantitative targeted proteomics approach to validate predicted microRNA targets in C. elegans , 2010, Nature Methods.

[10]  Ronald J. Moore,et al.  Enhanced Sensitivity for Selected Reaction Monitoring Mass Spectrometry-based Targeted Proteomics Using a Dual Stage Electrodynamic Ion Funnel Interface* , 2010, Molecular & Cellular Proteomics.

[11]  Brendan MacLean,et al.  Skyline: an open source document editor for creating and analyzing targeted proteomics experiments , 2010, Bioinform..

[12]  Jason M. Held,et al.  Targeted Quantitation of Site-Specific Cysteine Oxidation in Endogenous Proteins Using a Differential Alkylation and Multiple Reaction Monitoring Mass Spectrometry Approach , 2010, Molecular & Cellular Proteomics.

[13]  Amanda G. Paulovich,et al.  An Automated and Multiplexed Method for High Throughput Peptide Immunoaffinity Enrichment and Multiple Reaction Monitoring Mass Spectrometry-based Quantification of Protein Biomarkers* , 2009, Molecular & Cellular Proteomics.

[14]  Lukas N. Mueller,et al.  Full Dynamic Range Proteome Analysis of S. cerevisiae by Targeted Proteomics , 2009, Cell.

[15]  R. Aebersold,et al.  Proteome-wide cellular protein concentrations of the human pathogen Leptospira interrogans , 2009, Nature.

[16]  Xu Shi,et al.  Quantification of Cardiovascular Biomarkers in Patient Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution* , 2009, Molecular & Cellular Proteomics.

[17]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[18]  D R Mani,et al.  Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. , 2009, Clinical chemistry.

[19]  A. Salvador,et al.  Clinical Quantitation of Prostate-specific Antigen Biomarker in the Low Nanogram/Milliliter Range by Conventional Bore Liquid Chromatography-Tandem Mass Spectrometry (Multiple Reaction Monitoring) Coupling and Correlation with ELISA Tests , 2009, Molecular & Cellular Proteomics.

[20]  Christoph H Borchers,et al.  Multiple Reaction Monitoring-based, Multiplexed, Absolute Quantitation of 45 Proteins in Human Plasma* , 2009, Molecular & Cellular Proteomics.

[21]  Gennifer E. Merrihew,et al.  Expediting the development of targeted SRM assays: using data from shotgun proteomics to automate method development. , 2009, Journal of proteome research.

[22]  Andrew N Hoofnagle,et al.  Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. , 2008, Clinical chemistry.

[23]  R. Aebersold,et al.  Selected reaction monitoring for quantitative proteomics: a tutorial , 2008, Molecular systems biology.

[24]  David T. Kaleta,et al.  Enhanced Detection of Low Abundance Human Plasma Proteins Using a Tandem IgY12-SuperMix Immunoaffinity Separation Strategy*S , 2008, Molecular & Cellular Proteomics.

[25]  G. Nicol,et al.  Use of an Immunoaffinity-Mass Spectrometry-based Approach for the Quantification of Protein Biomarkers from Serum Samples of Lung Cancer Patients* , 2008, Molecular & Cellular Proteomics.

[26]  S. Carr,et al.  Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S , 2007, Molecular & Cellular Proteomics.

[27]  D. Lauffenburger,et al.  Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks , 2007, Proceedings of the National Academy of Sciences.

[28]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2006, Oncogene.

[29]  Ronald J. Moore,et al.  Evaluation of Multiprotein Immunoaffinity Subtraction for Plasma Proteomics and Candidate Biomarker Discovery Using Mass Spectrometry*S , 2006, Molecular & Cellular Proteomics.

[30]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[31]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[32]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[33]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[34]  S. Gygi,et al.  Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. G. Das,et al.  Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10) , 2000, Clinical chemistry.

[36]  A. Semjonow,et al.  Discordance of assay methods creates pitfalls for the interpretation of prostate‐specific antigen values , 1996, The Prostate. Supplement.

[37]  J. Oesterling,et al.  Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. , 1995, Urology.

[38]  T. Stamey,et al.  Clinical usefulness of free and complexed PSA. , 1995, Scandinavian journal of clinical and laboratory investigation. Supplementum.